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Abstract
Background and aim: The adhesion molecule expression and matrix metalloproteinases (MMPs)
are proposed to be major factors for intestinal injury mediated by T cells in (IBD) and are
up-regulated in intestinal mucosa of IBD patients. To investigate the effect of vitamin D
derivatives on adhesion molecules and MMPs in colonic biopsies of IBD patients.
Methods: Biopsies from inflamed and non-inflamed tract of terminal ileum and colon and PBMC
from the same IBD patients were cultured with or without vitamin D derivatives. MMP activity
and adhesion molecule levels were determined.
Results: 1,25(OH)2D3 and ZK 191784 significantly decrease ICAM-1 protein levels in the biopsies
obtained only from the inflamed region of intestine of UC patients, while MAdCAM-1 levels
decrease in the presence of 1,25(OH)2D3 in the non-inflamed region, and, in the presence of ZK,
in the inflamed one. In CD patients 1,25(OH)2D3 and ZK decrease ICAM-1 and MAdCAM-1 in the
biopsies obtained from the non-inflamed and inflamed regions, with the exception of ICAM-1 in
the inflamed region in the presence of 1,25(OH)2D3. The expression of MMP-9, MMP-2, and MMP-3
decreases in the presence of vitamin D derivatives in UC and CD with the exception of
1,25(OH)2D3 that does not affect the levels of MMP-9 and MMP-2 in CD. Vitamin D derivatives
always affect MMP-9, MMP-2 and ICAM-1 in PBMC of UC and CD patients.5 4598 330; fax: +39 055 4598 905.
(M. Stio).
014.02.005
nd Colitis Organisation. Published by Elsevier B.V. All rights reserved.
1063Vitamin D and inflammatory bowel diseasesConclusions: Based on the increased expression of ICAM-1, MAdCAM-1 and MMP-2,-9,-3 in IBD,
our study suggests that vitamin D derivatives may be effective in the management of these
diseases.
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Crohn's disease (CD) and ulcerative colitis (UC) are the two
main phenotypes of inflammatory bowel diseases (IBD), which
are chronically relapsing intestinal inflammatory conditions,
associated with a disregulation of the mucosal immune
system.1,2 A complex inflammatory cascade is responsible for
the development and chronicity of the lesions, and in both CD
and UC an increased production of proinflammatory cytokines
is associated with the initiation and progression of the
disease.3,4 In the areas of chronic mucosal inflammation and
ulcerations of the gut wall a key role is played by various
metalloproteinases (MMPs), which serve as effectors of cell
migration, cytotoxicity and tissue remodelling via degradation
of ECM components. MMPs, which are influenced by many
proinflammatory cytokines5,6 are therefore proposed to be
major factors for intestinal injury mediated by T cells in IBD.7
The activity of MMPs is strictly regulated by their natural
inhibitors, the tissue inhibitors of MMPs (TIMPs).8 A distur-
bance of the regulated balance between MMPs and TIMPs has
been implicated in the pathogenesis of IBD.9
Among MMPs, MMP-2 and MMP-9 (gelatinase A and B) are
endoproteases, which, upon activation, mediate immune cell
extravasation via proteolysis of basement membranes.10,11
MMP-2, most commonly expressed enzyme in normal tissue, is
primarily produced by stromal cells, while MMP-9 is mainly
synthesized by inflammatory cells, particularly by polymor-
phonuclear leucocyte.12 MMP-9 plays a key role in the patho-
genesis of inflammatory diseases and it has been found to be
up-regulated in immune cells during active flares of IBD in
humans.7,13 Pedersen et al.14 reported that mRNA levels for
MMP-3 and MMP-9 were increased significantly in colonic
epithelial cells from inflamed areas compared with macro-
scopic non-inflamed areas, taken in parallel from the same
patient. Therefore, in chronic inflammation, inhibition of
MMP-activities may be desired. In addition to their direct
effects on ECM, there is evidence that MMPs are also involved in
the recruitment of inflammatory cells into the intestine.15,16
Several studies have examined the expression of mucosal
adhesion molecules in chronic IBD, showing that intracellular
adhesion molecules play an important role in the recruitment
of leucocytes at sites of inflammation and are up-regulated in
intestinal mucosa of IBD patients.17 In IBD, lymphocyte
infiltration into the intestinal tract is mainly mediated by the
interaction between α4β7 integrin, expressed on lymphocytes,
and its specific ligand mucosal addressin CAM-1 (MAdCAM-1),
expressed on the endothelial cells of the microvasculature in
the inflamed intestinal tract. Vedolizumab is a selective
humanized IgG1 monoclonal antibody against α4β7 integrin
resulting in a specific blockade of gut-homing lymphocytes. Of
interest, recently Sandborn et al.18 have conducted integrated
induction and maintenance trials of vedolizumab, in patients
with moderately to severely active CD. Vedolizumab-treated
patients with active CD were more likely than patientsreceiving placebo to achieve the remission. Similarly, Feagan
et al.19 have conducted two integrated randomized, double-
blind, placebo-controlled trials of vedolizumab in patients with
active UC, and reported that vedolizumab was more effective
than placebo for induction and maintenance of remission.
Intercellular adhesion molecule-1 (ICAM-1) is an inducible
transmembrane glycoprotein of the immunoglobulin family
that is constitutively expressed on vascular endothelial cells
and on a subset of leucocytes. Inflammatory cytokines, such as
TNF-α and IL-1, induce the presence of ICAM-1, of selectin, and
probably also of MAdCAM-1 on the endothelium in inflamed
tissue.20 Moreover, the expression of ICAM-1 in CD is increased
not only in the intestinal mucosa but also in the submucosa and
in the muscle layers.21 ICAM-1 has also been shown to increase
in the serum of IBD patients, correlating with disease
activity.22,23 Molecules that block interactions between adhe-
sion molecules present on circulating immune cells and their
endothelial cell receptors could decrease the migration of
these cells through the endothelium and, therefore, decrease
chronic inflammation. The hormonally active form of vitamin
D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] exerts its action by
binding to the vitamin D receptor (VDR), an inducible
transcription factor that influences the transcription of various
genes, whose products are also involved in the regulation of
the immune response24 in many experimental autoimmune
diseases, among which IBD, where systemic therapy with
1,25(OH)2D3 results in significant inhibition of disease symp-
toms, or prevention of disease onset.25 Vitamin D may protect
against the development of IBD. Several studies suggest that
these effects may be partly mediated by genetic variants of
VDR. In fact, several polymorphisms have been identified in
VDR gene, however, their role in the predisposition to UC and
CD is conflicting.26 Moreover, a link between vitamin D
availability, either from sunshine or diet, and the prevalence
of IBD has been reported.27 In addition, vitamin D deficiency is
common in patients with IBD.28
In our previous studies the immunosuppressive role of
vitamin D derivatives in IBD, and their potential therapeutic
role was reported.29–32 New vitamin D analogues with selective
immunoregulatory properties and lower hypercalcemic effects
than those of 1,25(OH)2D3 have been developed. One of these
is ZK 191784 (ZK), characterised by a 22,23-double bond,
24R-hydroxy group, 25-cyclopropyl ring, and 5-butyloxazole
unit, which shows a therapeutic advantage over 1,25(OH)2D3 by
inducing immunosuppressive effects also at concentrations
that do not cause hypercalcemia.33 This vitamin D analogue
competitively binds to VDR with a similar affinity as
1,25(OH)2D3, inhibits antigen-induced lymphocyte prolifera-
tion and cytokine secretion “in vitro” and displays a unique
tissue-specific profile when administered “in vivo”.34 More-
over, in experimental colitis induced inmice by dextran sodium
sulphate, ZK demonstrated significant anti-inflammatory prop-
erties that were at least partially mediated by its immunosup-
pressive effects on mucosal dendritic cells.35 It would be
Table 2 Definition of Crohn's disease phenotype according
to the Montreal classification.
Pts Sex Yrs A L B
1 M 46 (26) A2 L3 B2
2 M 37 (13) A1 L3 B1
3 M 45 (19) A2 L3 B1
4 F 67 (41) A3 L2 B1
1064 M. Martinesi et al.therefore relevant to test the action of both 1,25(OH)2D3 and
ZK 191784 in biopsies obtained from the un-inflamed and
inflamed areas of the intestine of IBD patients.
The aim of the present study was to demonstrate whether
the vitamin D derivatives down-regulate adhesion molecules
and decrease MMP production in biopsies of IBD patients,
suggesting therefore that these molecules may represent a
potential target for the treatment of IBD.5 F 66 (42) A3 L1 B2
6 F 39 (18) A2 L2 B1
7 M 44 (23) A2 L2 B1
Abbreviations:
Pts = Patients, S = Sex, Yrs = Years at the time of sampling (and
at diagnosis), A = Age at diagnosis, L = Location, B = Behaviour.2. Materials and methods
2.1. Patients
After obtaining informed consent for this study from all
patients, biopsies were taken at routine diagnostic colonos-
copies from patients with IBD. Seven CD patients (four men
and three women with a mean age of 49.2, range 37–67 yr
old), seven UC patients (four men and three women with a
mean age of 48.0, range 31–65 yr old) with active disease,
and five healthy subjects (three men and two women with
a mean age of 52.5 range 44–66 yr old) were studied. The
healthy controls were selected in an age range similar to
that of patients, among subjects undergoing endoscopic
screening for colon cancer prevention. The diagnosis of CD
and UC was established on the basis of clinical symptoms and
on endoscopic, histological, radiological demonstration and
pathologic criteria, as described by Lennard-Jones.36 UC and
CD were defined according to the Montreal classification.37
These data are reported in Tables 1 and 2. Biopsy samples
were taken from (I) inflamed and (NI) non-inflamed area.
The histological assessments at biopsies sites confirmed the
severity of inflammation.
In E1 UC patients, samples were taken from I: rectum and
NI: sigmoid colon.
In E2 patients, samples were taken from I: rectum and
sigmoid colon and NI: from transverse colon.
In E3 patients, samples were taken from I: rectum and
transverse colon and NI: from caecum or ascending colon.
IN CD patients, number 1, 2, 3 and 5 (I) biopsies were
taken from the inflamed terminal ileum. In CD patients
number 4, 6, and 7 (I) biopsies were taken from the inflamed
colon. NI biopsies were taken from the non-inflamed colonic
mucosa. CD patients with perianal or proximal disease were
not included in the present study.Table 1 Definition of ulcerative colitis phenotype according
to the Montreal classification.
Pts Sex Age E S
1 M 31 E3 S2
2 M 64 E3 S2
3 M 32 E1 S2
4 F 33 E3 S2
5 M 52 E3 S2
6 F 65 E3 S2
7 F 59 E2 S2
Abbreviations:
Pts = Patients, S = Sex, A = Age at the time of the sampling, E =
Maximal Extent at any time, S = Severity.PBMC were obtained by the same patients, from which
colonic biopsies were taken.
2.2. Materials
RPMI 1640 medium Hepes modification, PBS, heat inactivated
FBS, L-glutamine and antibiotics were obtained from Sigma (St.
Louis, MO). 1 × 10−2 M ZK 191784 in ethanol was a generous gift
from Bayer Schering Pharma Aktiengesellschaft. 1,25(OH)2D3 in
isopropanol was a generous gift from Dr. Lise Binderup (Leo
Pharmaceutical Products). Stock solutions were stored at
−20 °C, protected from light and freshly diluted in culture
medium before each experiment. VDR, ICAM-1, MAdCAM-1,
MMP-3 and β-actin antibodies, and horseradish peroxidase-
conjugated secondary antibodies were obtained from Santa
Cruz Biotechnology (California, USA). All other chemicals were
the highest grade available from E. Merck (Darmstadt,
Germany), Sigma (St. Louis, MO), and Bio-Rad Laboratories.
2.3. PBMC isolation and culture conditions
PBMC were obtained from UC and CD patients by density
gradient (1.077) centrifugation (30 min at 400 ×g) of heparin-
ized venous blood diluted 1:2 with PBS on Ficoll-Paque. About
95% of mononuclear cells at the interface, containing PBMC,
was collected and washed twice with PBS. Viability of PBMC
was determined by Trypan blue exclusion test. The cells were
always viable in all the experimental conditions used.
Biopsies and PBMC (2 × 106 cells) were cultured for 24 h
and 48 h, respectively, in RPMI 1640 supplemented with
25 mM Hepes, 10% (v/v) heat inactivated FBS, 60 mg/l
(100 U/ml) penicillin, 100 mg/l streptomycin, 0.29 g/l
L-glutamine, and incubated in the presence of vehicle alone
or 100 nM 1,25(OH)2D3 or 1 μM ZK. PBMC were incubated with
10 μg/ml PHA used alone or in association with 100 nM
1,25(OH)2D3 or 1 μM ZK. The cultures were maintained at
37 °C in a humidified atmosphere containing 5% CO2. At the
end of the incubation with the compounds the medium was
collected and used for the determination of MMP activity
(MMP-9 and MMP-2). Biopsies and PBMC, collected by scraping
adherent monocytes, were homogenized in lysis buffer
(10 mM Hepes, 150 mM NaCl, 1 mM EDTA 0.6% NP-40,
0.5 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml aprotinin, and
0.5 μg/ml pepstatin). The homogenate was centrifuged at
10,000 ×g for 15 min at 4 °C, and the supernatant was used
for protein determination and Western blot analysis.
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Protein concentration was determined by the Bradford
method,38 using bovine serum albumin as standard.2.5. Western blot analysis
Total cell lysates from intestinal biopsies and PBMC were
prepared and equal proteins were electrophoresed on SDS 10%
polyacrylamide gel. Electrophoresed proteins were transferred
onto pure PVDF membranes (Bio-Rad Laboratories), as reported
by Laemmli.39 After transfer, themembraneswerewashedwith
TPBS at room temperature, incubated overnight at 4 °C with
the opportune primary antibody (VDR or ICAM-1 or MAdCAM-1 or
MMP-3), washed again, and then incubated for 60 min with the
relative secondary antibody. The membranes, after three
washes with TPBS, were treated with the chemiluminescent
substrate and enhancer (ECL or ECL plus, Amersham). Blots
were analysed by Chemi-Doc (Bio-Rad) utilising the Quantity
One programme (Bio-Rad). Protein bandswere normalized using
the respective β-actin protein band. Densitometric data are
given relative to vehicle, set equal to 100.2.6. Zymography
MMP-9 and MMP-2 gelatinase activity was visualised by
zymography. Briefly, SDS polyacrylamide gels (8%) containing
0.1% gelatine were overlaid with 4% stacking gels. Sample
supernatants were mixed (10:1 volume) with a sample buffer
consisting of 50 mM Tris–HCl, pH 6.8, 2% SDS, 20% glycerol,
and 0.03% bromophenol blue. After the loading of the samples,
electrophoresis was carried out at 125 V for 2 h. After
electrophoresis, the gels were soaked in 2.5% Triton X-100 on
a shaker for 1 h, at room temperature, changing the solution
after 30 min, to eliminate SDS. The gels were then equilibrat-
ed for 30 min with the digestion buffer (50 mM Tris–HCl,
pH 7.5, 5 mM CaCl2, 200 mM NaCl) at room temperature with
gentle agitation, then replaced with fresh digestion buffer and
incubated at 37 °C overnight. The gels were then stained for
1–2 h with 0.5% Coomassie Brilliant Blue in 30% methanol and
10% acetic acid and destained with 30% methanol and 10%
acetic acid, after which clear bands of digested gelatine were
clearly visible. The gels were scanned by Chemi-Doc (Bio-Rad),
utilising the Quantity One programme (Bio-Rad).Figure 1 Effects of vitamin D derivatives on VDR. VDR protein
levels were determined by Western blot analysis in intestinal
biopsies obtained from healthy subjects (HS) and from non-
inflamed (NI) and inflamed (I) intestinal regions of ulcerative
colitis (UC) and Crohn's disease (CD) patients after 24-h incubation
with 100 nM 1,25(OH)2D3 (D) or 1 μM ZK 191784 (ZK). The
densitometric values, normalized with the use of the respective2.7. Statistical methods
Statistical significance was determined by either one-way
ANOVA followed by a Bonferroni t test or by a Student's t-test.
One-way analysis of variance was used to determine significance
among groups, after which the modified t test with the
Bonferroni correction was used for comparison between individ-
ual groups. Differences were considered significant at P b 0.05.β-actin protein band, are reported as the percentage of the cells
treated with vehicle alone (V). The vehicle was represented by
the culture medium with ethanol or isopropanol at the same
concentration used in the experiments with vitamin D derivatives.
Each densitometric value represents the mean ± S.D. of three
separate experiments. ⁎⁎P b 0.05 (in comparison with vehicle
alone). ⁎P b 0.01 (in comparison with vehicle alone).2.8. Ethical consideration
The study was approved by the Medical Ethics Committee,
CE 2 maggio 2011, protocol 0016888, rif. 95/10
(Division of Gastroenterology 2, Careggi Hospital, 50134Florence, Italy). Informed consent was obtained from all
subjects.
3. Results
3.1. 1,25(OH)2D3 and ZK 191784 influence VDR
protein levels in intestinal biopsies of HS, UC
and CD patients
The effects of 1,25(OH)2D3 (D) and ZK 191784 (ZK) on VDR
protein levels in intestinal biopsies of HS, UC and CD patients
are depicted in Fig. 1. With the exception of the incubation
with 1,25(OH)2D3 in biopsies obtained from the non-inflamed
intestinal region of CD patients, in all the other cases a
significant increase in VDR protein levels is registered in the
presence of 1,25(OH)2D3 or ZK, the highest values being
obtained in biopsies of healthy subjects.
3.2. 1,25(OH)2D3 and ZK 191784 influence ICAM-1
and MAdCAM-1 protein levels in intestinal biopsies
of HS, UC and CD patientsThe effects of 1,25(OH)2D3 (D) and ZK 191784 (ZK) on ICAM-1
and MAdCAM-1 protein levels in intestinal biopsies of HS, UC
and CD patients are depicted in Fig. 2 (A, B, C, respectively).
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protein levels, which, on the contrary, are significantly
decreased by the incubation with ZK. Both 1,25(OH)2D3 and
ZK remarkably decrease MAdCAM-1 protein levels.
From Fig. 2B, it may be observed that, in UC patients,
neither 1,25(OH)2D3 nor ZK induce a decrease on ICAM-1
protein levels in the biopsies obtained from the non-inflamed
region of intestine, but 1,25(OH)2D3 induce a slight increase.
On the contrary these levels are significantly decreased by
these two vitamin D derivatives in the inflamed region.
MAdCAM-1 protein levels decrease in the presence of
1,25(OH)2D3 in the non-inflamed region, and of ZK in the
inflamed one. This decrease is particularly accentuated in theFigure 2 A, B and C: Effects of vitamin D derivatives on ICAM
determined by Western blot analysis in intestinal biopsies obtained
inflamed (I) intestinal regions of ulcerative colitis (UC) (B) and Croh
1,25(OH)2D3 (D) or 1 μM ZK 191784 (ZK). The densitometric values,
are reported as the percentage of the cells treated with vehicle alon
ethanol or isopropanol at the same concentration used in the exp
represents the mean ± S.D. of three separate experiments. ⁎⁎P b 0.
with vehicle alone).inflamed region in the presence of ZK, while ZK induces a
slight increase on NI tract. The comparison between ICAM-1
levels determined in biopsies obtained from non-inflamed and
inflamed regions of intestine and incubated with vehicle alone
(Table 3) indicates that these levels are higher in the inflamed
region in comparison with the non-inflamed one, with an
increase of about 545%. The increase in MAdCAM-1 levels in
the inflamed region compared with the non- inflamed one is
about 150%.
In CD patients (Fig. 2C), both 1,25(OH)2D3 and ZK decrease
the levels of ICAM-1 and MAdCAM-1 in the biopsies obtained
from the non-inflamed and inflamed regions, with the ex-
ception of ICAM-1 in the inflamed region, which is not affected-1 and MAdCAM-1. ICAM-1 and MAdCAM-1 protein levels were
from healthy subjects (HS) (A) and from non-inflamed (NI) and
n's disease (CD) (C) patients after 24-h incubation with 100 nM
normalized with the use of the respective β-actin protein band,
e (V). The vehicle was represented by the culture medium with
eriments with vitamin D derivatives. Each densitometric value
05 (in comparison with vehicle alone). ⁎P b 0.01 (in comparison
1067Vitamin D and inflammatory bowel diseasesby the incubation with 1,25(OH)2D3. The highest inhibition is
observed in the inflamed region for MAdCAM-1 in the presence
of ZK. Here the comparison between ICAM-1 levels, deter-
mined in biopsies obtained from non-inflamed and inflamed
regions (Table 3) of intestine and incubated with vehicle
alone, shows that these levels are higher in the inflamed
region in comparison with the non-inflamed one, with an
increase of about 300%. The increase in MAdCAM-1 levels in
the inflamed region compared with the non-inflamed one is of
about 175%.3.3. 1,25(OH)2D3 and ZK 191784 influence ICAM-1
protein levels in PBMC of UC and CD patients
The results, reported in Fig. 3, indicate that ICAM-1 levels
significantly decrease when PBMC of both UC and CD patients
were incubated with vitamin D derivatives compared to the
cell stimulated with PHA alone.Figure 3 Effects of vitamin D derivatives on ICAM-1. ICAM-1
protein levels were determined by Western blot analysis in PBMC
obtained from ulcerative colitis (UC) and Crohn's disease (CD)
patients after 48 h incubation with 100 nM1,25(OH)2D3 (D) or 1 μM
ZK 191784 (ZK). The densitometric values, normalized with the
use of the respective β-actin protein band, are reported as the
percentage of the cells treated with vehicle alone (V). The
vehicle was represented by the culture medium with ethanol or
isopropanol at the same concentration used in the experiments
with vitamin D derivatives. Each densitometric value represents
the mean ± S.D. of three separate experiments. ⁎P b 0.01 (in
comparison with vehicle alone).3.4. 1,25(OH)2D3 and ZK 191784 influence
metalloproteinase protein levels in intestinal
biopsies of HS, UC and CD patients
In HS (Fig. 4A) 1,25(OH)2D3 is able to significantly decrease
MMP-3 levels, while it is ineffective on MMP-9 and MMP-2. On
the contrary, all the MMP studied decreased after the treat-
ment of the biopsies with ZK, this effect being particularly
remarkable for MMP-9.
In UC, Fig. 4B, with the exception of MMP-3 levels deter-
mined in the non-inflamed region, which are not influenced
by 1,25(OH)2D3, all the other determinations indicate that
both 1,25(OH)2D3 and ZK significantly decrease the levels of
the MMPs under study. This effect is always noteworthy in
the presence of ZK. Indeed, the levels of MMP-9 in the non-
inflamed region were undetectable, when ZK was present.
From Fig. 4C, which depicts the results obtained with the
biopsies of CD patients, it may be observed that 1,25(OH)2D3
does not affect the levels of MMP-9 and MMP-2, while it
significantly decreases those of MMP-3. On the other hand,
ZK always decreases the levels of the three MMPs in the
non-inflamed region and in the inflamed one.
The comparison between MMP levels determined in
biopsies obtained from non-inflamed and inflamed regions
of intestine obtained from UC and CD patients incubated
with vehicle alone shows that these levels are higher in the
inflamed region in comparison with the non-inflamed one.
The results are reported in Table 3.Table 3 Values of MMPs, adhesion molecules and VDR vehi-
cles from the inflamed tracts of UC and CD patients, referred
to the non-inflamed ones, set equal to 100.
Patients MMP-9 MMP-2 MMP-3 ICAM-1 Mad-CAM VDR
UC 800 325 190 545 150 62
CD 500 290 480 300 175 443.5. 1,25(OH)2D3 and ZK 191784 influence
metalloproteinase in PBMC of UC and CD patients
The levels of MMP-9 and MMP-2, released in the culture
medium by PBMC obtained from UC and CD patients, are
reported in Fig. 5. The results obtained indicate that MMP-9
and MMP-2 production by PBMC of both UC and CD patients
significantly decreases incubating the cells with the vitamin
D derivatives. The highest decrease is observed for MMP-9
incubating the cells with ZK in UC patients.
4. Discussion
IBD are characterised by high intestinal turnover during the
sequence of inflammation, tissue destruction and healing.
Recruitment of cells to diseased intestinal mucosa is essential
to the initiation and perpetuation of IBD. The recruitment
involves activation of a number of adhesion molecules and
their ligands on leucocytes and vascular endothelium.
MAdCAM-1 plays a central role in the aetiology of IBD through
its ability to direct circulating lymphocytes to enter gut-
associated lymphoid tissue and gut interstitium.
In this study we examined the action of 1,25(OH)2D3 and
the vitamin D analogue ZK 191784 on biopsies obtained from
Figure 4 A, B and C: Effects of vitamin D derivatives on MMPs. Activity of MMP-9, and MMP-2 was measured by zymography, MMP-3
protein levels were determined by Western blot analysis in intestinal biopsies obtained from healthy subjects (HS) (A) and from
non-inflamed (NI) and inflamed (I) intestinal regions of ulcerative colitis (UC) (B) and Crohn's disease (CD) (C) patients after 24 h
incubation with 100 nM 1,25(OH)2D3 (D) or 1 μM ZK 191784 (ZK). The densitometric values are reported as the percentage of the cells
treated with vehicle alone (V). The vehicle was represented by the culture medium with ethanol or isopropanol at the same
concentration used in the experiments with vitamin D derivatives. Each densitometric value represents the mean ± S.D. of three
separate experiments. ⁎⁎P b 0.05 (in comparison with vehicle alone). ⁎P b 0.01 (in comparison with vehicle alone).
1068 M. Martinesi et al.non-inflamed and inflamed tract of gut of UC and CD patients,
with the aim to verify whether these substances could
decrease ICAM-1 and MAdCAM-1 levels. Our data indicate
that such levels are remarkably higher in the inflamed tract in
comparison with the non-inflamed one, confirming the data
reported in literature.40 Our results were homogeneous
despite the different sites of biopsy sampling (terminal ileum
and colon), being only dependent on the activity of the disease
(inflamed vs non inflamed areas). We have reported also the
data obtained from colonic biopsies of healthy subjects in
order to verify whether the response to the investigated
markers could be different comparing healthy subjects with
non-inflamed tract of IBD patients.The effect of vitamin D derivatives was also tested on MMP
(MMP-9,-2,-3) expression that we have previously shown to
increase in PBMC of IBD patients and to decrease in the
presence of the vitamin D analogue ZK 156979.32
The vitamin D derivatives, in particular the ZK, seem to be
effective in blocking the expression of adhesion molecules
responsible of inflammatory effects in IBD, thus suggesting
that ZK may be considered for further clinical development as
potential effective in the treatment of IBD.
In order to reduce ICAM-1 protein expression, the use in
therapy of ISIS-2302, a 20-base phosphorothioate antisense
oligodeoxynucleotide, was suggested in steroid refractory
Crohn's disease. Following the initial positive results,21 two
Figure 5 Effects of vitamin D derivatives on MMP-2 and
MMP-9. Activity of MMP-2 and MMP-9 was measured by zymo-
graphy on culture medium of PBMC obtained from ulcerative
colitis (UC) and from Crohn's disease (CD) after 48 h culture with
100 nM 1,25(OH)2D3 (D) or 1 μM ZK 191784 (ZK). PBMC. The
densitometric values are reported as the percentage of the cells
treated with vehicle alone (V). The vehicle was represented by
the culture medium with ethanol or isopropanol at the same
concentration used in the experiments with vitamin D deriva-
tives. Each densitometric value represents the mean ± S.D. of
three separate experiments. ⁎⁎P b 0.05 (in comparison with
vehicle alone). ⁎P b 0.01 (in comparison with vehicle alone).
1069Vitamin D and inflammatory bowel diseasessubsequent placebo-controlled trials failed to demonstrate
the efficacy.
The concomitant inhibitory effect of about 50% thatwe have
reported, on both colonic biopsies and PBMC, is interesting and
suggests a possible way to detect the clinical efficacy and the
inflammatory status in vitro.
This inhibitory effect may be mediated by the inhibition of
TNF-α production, similar to that we observed for PBMC in IBD
patients.32 Indeed, we have previously demonstrated that the
vitamin D analogue ZK 156979 down-regulates TNF-α produc-
tion by PBMC, and this decrease could be effective in the
inhibition of the MMP activities and adhesion molecules, both
increased in colonic mucosa and PBMC of IBD patients. In
addition, other authors have shown an up-regulation of MMPs
and ICAM-1 in intestinal tissue of patients with IBD with a
significant improvement after administration of the anti-TNF-α
antibody infliximab.41,21
The inhibitory effect on adhesion molecules is a genomic
effect mediated by VDR, whose level increases when the
biopsies are incubated with ZK, suggesting that ZK exerts its
effects by binding to VDR.
Recently Lees et al.42 have reported that Hedgehog (Hh)
signalling through Gli1 is required for appropriate modula-
tion of the intestinal response to acute inflammatory
challenge. Reduced Gli1 function predisposes to a height-
ened myeloid response to inflammatory stimuli, potentially
leading to IBD. The functional relevance of Gli1 is demon-
strated by the severe intestinal inflammation that developsin the face of a 50% reduction in Gli1 concentration in an
established mouse model of colitis.
Moreover, Uhmann et al.43 report an increased Hh pathway
activity in the Patched Mouse Model of Embryonal Rhabdo-
myosarcoma (ERMS) and demonstrate that the treatment with
the active form of vitamin D3, calcitriol, inhibits Hh signalling
and proliferation of murine ERMS in vivo and in vitro.
Concomitantly, calcitriol activates VDR signalling and
induces tumour differentiation. These authors suggest that
exogenous supply of calcitriol could be beneficial in the
treatment of rhabdomyosarcoma, the most common soft
tissue sarcoma in children, especially in those associated
with aberrant Hh signalling activity.
In the present study we have demonstrated that vitamin
D derivatives affect adhesion molecules and MMP activating
VDR signalling, but we have not investigated if this effect is
genetically determined, implicating the Hedgehog (Hh)
signalling. Some authors44 report that vitamin D decreases
Gl2 expression in tumours without detecting VDR in total
protein extracts from tumours, thus dissociating the possible
activity of vitamin D3 on human clear renal cell carcinoma
(CCC) through VDR.
The inhibitory effect, exerted by the vitamin D derivatives
on both colonic mucosa and PBMC, is relevant, as vitamin D is
supposed to exert a role in IBD. Moreover a recent study
reports a correlation between MMP-9 serum activity and the
activity of disease.45 This correlation could be useful in the
prediction of CD activity status, as the intensity of the disease
process in intestinal tract is reflected by MMP concentrations
in the blood. Therefore, the vitamin D derivatives could be
potentially utilised for controlling the disease activity and the
inflammation. The impact of this research is interesting, as
other authors46 observed that serum concentration of MMP-9
was significantly higher in UC and CD patients compared with
controls.
Many MMPs, including MMP-2 and MMP-9 are highly ex-
pressed in inflamed tissue of IBD patients. MMP-9 is produced
by epithelial cells during experimental colitis.47 MMP-9 null
mice have a less severe colitis in response to the administration
of dextran sodium sulphate, thus suggesting that the blocking
of MMP-9 may be of potential therapeutic benefit in IBD.47
Many studies have demonstrated that several MMP in-
hibitors significantly reduce tissue injury in animal models
of inflammatory bowel disease,48–51 indicating that MMP
inhibitors may be candidates for the treatment of IBD.
Among the numerous MMPs, MMP-9 may be considered a
key enzyme responsible for accelerated breakdown of ECM
in UC, because its expression is higher in patients with UC in
comparison with controls.12 These data are in agreement
with those reported in this study in which MMP levels were
higher in the inflamed regions of intestine in comparison
with the non-inflamed ones. Other authors have reported
that MMP-2 and MMP-9 are enhanced in intestinal tissue
and seem to be actively involved in the inflammatory and
remodelling processes in IBD, without major differences
between CD and UC.9 Our results that report a significantly
inhibitory effect on MMP-9 and MMP-2 in colonic biopsies of
IBD patients are in accordance with those obtained in PBMC
of UC and CD patients.
Also MMP-3 is important in the tissue environment for
migration of CD4+ T lymphocytes into the lamina propria.52
Endothelial cells can make MMP-3, and there is a possibility
1070 M. Martinesi et al.that, when an intestine-homing CD4+ cell binds to a MAdCAM-1
positive vessel in the colon, it signals the endothelial cells to
release MMP-3 into the pericellular space to open up tight
junctions, allowing the lymphocytes to migrate through. We
have demonstrated that vitamin D derivatives may affect also
MMP-3.
In conclusion, based on the increased expression of
ICAM-1, MAdCAM-1 and MMP-2,-9,-3, in the inflamed areas
of the gut of IBD patients and the inhibitory effects of
vitamin D derivatives as we found in the present study, we
hypothesize that adhesion molecules and MMPs are potential
targets of vitamin D derivatives with possible efficacy in the
management of these diseases.
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